crazy leaf tirzepatide gip glp 1 drops Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction As GLP-1 weight-loss drugs surged

The figure below shows the proportion of patients who lost over 5, 10, and 15% during trials of Ozempic and Wegovy

The mechanism by which GLP-1 RAs potentially increase suicide or suicide attempts is unclear but may involve an overactivation of the hypothalamic-pituitary-adrenal (HPA) axis [7], rapid weight loss [8], and reduced expression of brain-derived neurotrophic factor which may link weight changes to heightened anxiety and suicidal risk [9]

In fact, a quinoxaline (compound 2) and a pyrimidine (compound B) act in an additive manner to activate the GLP-1R under conditions in which the receptor is truncated to remove the N-terminal extracellular domain at which the C-terminus of GLP-1 binds

All other agents are selective GLP-1 RAs